CNRS Technologies

Find the best CNRS technologies to boost your innovative project.

Newest patents

You are a research scientist?

We can guide you through the whole technology transfer process.

See all our services

You are a corporate player?

Thanks to our expertise, our network and our know-how of the innovation ecosystem, we support you throughout your project.

Contact us

Follow our news and upcoming events

Discover CNRS technologies

Meet our team

Close

Imaging agents for tumor diagnosis and intraoperative imaging

Reference

04859-01

Patents status

Priority patent application n° FR 11 02213 filed on July 13, 2011, entitled “Nouveaux agents d’imagerie, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent”

Inventors

Alain LE PAPE
Stéphanie LERONDEL
Guillaume REVEILLON
Jean-Marie DELBOS
Luc DEMUYNCK
Hubert GRANDON
François LEFOULON
Gordon TUCKER

commercial status

Exclusive or non-exclusive license

Laboratory

Transgenèse et archivage d’animaux modèles (TAAM /UPS44) -Centre d’Imagerie du Petit Animal (CIPA) in Orléans, France

Description

CONTEXT

The direct imaging of living cells has become a fundamental tool to study biological processes in real-time, noninvasively, directly within a living organism.
Despite real progress in noninvasive imaging, methods and imaging agents that are more sensitive and more specific are still necessary. In particular, it is advantageous to have probes able to detect a broader spectrum of tumor types, to improve the contrast between the tumor zone and non-specific sites, and to minimize accumulation in healthy tissues.
Integrins are transmembrane cell adhesion receptors located on the cell’s surface which bind to molecules of the extracellular matrix. In particular, αVβ3 and αVβ5 integrins are expressed in many tumor cells such as glioblastoma, melanoma, and carcinomas of breast and ovaries. αVβ3 and αVβ5 integrins are strongly expressed in activated endothelial cells during tumor neovascularization but relatively absent in quiescent endothelial cells and in most healthy tissues. And clinical observations have shown a direct correlation between integrin expression rates and tumor progression. Consequently, αVβ3 and αVβ5 integrins are an attractive target in the detection of tumor and metastatic growth.

TECHNICAL DESCRIPTION

This invention concerns novel imaging agents comprising an integrin receptor targeting ligand, the process for the preparation thereof, and pharmaceutical compositions containing same and use thereof for diagnostic purposes.

BENEFITS

These compounds have important advantages over current imaging agents:

  • Detection of a broader spectrum of tumor types
  • Excellent discrimination between healthy tissue and tumor structures
  • Minimum accumulation in healthy tissues

INDUSTRIAL APPLICATIONS

The main application is in the oncology area. This innovation could be used for:

  • In vivo imaging / In vivo diagnosis : especially for diagnostic imaging of hard to detect cancers and in situations where the tumour environment complicates precise discrimination between healthy tissue and tumour structures. It is a matter in particular of deep thoracic and abdominal areas having tissue or vascular background noise in intraoperative imaging or fibroscopic imaging.
  • Drug development / Screening

For further information, please contact us (Ref 04859-01)

Need further information ?

Contact us
Close

Contact us

  • This field is for validation purposes and should be left unchanged.
Close

Newest patents